A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor

Psoriatic arthritis (PsA) is a unique inflammatory arthritis due to the fact that patients have to deal not only with pain but also with their skin appearance, which may have a detrimental effect on their everyday lives and psychology. Treating a patient with PsA, improving both the musculoskeletal...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelechas, Eleftherios, Memi, Tereza, Voulgari, Paraskevi V., Drosos, Alexandros A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696296/
https://www.ncbi.nlm.nih.gov/pubmed/29022197
http://dx.doi.org/10.1007/s40744-017-0084-0
_version_ 1783280421750964224
author Pelechas, Eleftherios
Memi, Tereza
Voulgari, Paraskevi V.
Drosos, Alexandros A.
author_facet Pelechas, Eleftherios
Memi, Tereza
Voulgari, Paraskevi V.
Drosos, Alexandros A.
author_sort Pelechas, Eleftherios
collection PubMed
description Psoriatic arthritis (PsA) is a unique inflammatory arthritis due to the fact that patients have to deal not only with pain but also with their skin appearance, which may have a detrimental effect on their everyday lives and psychology. Treating a patient with PsA, improving both the musculoskeletal and skin symptoms is a challenge for the clinical rheumatologist. In this case, we present a patient of recalcitrant PsA to tumor necrosis factor inhibitors (TNFi) who had an exceptional improvement after administration of the interleukin-17A inhibitor (IL-17Ai) secukinumab.
format Online
Article
Text
id pubmed-5696296
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-56962962017-12-04 A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor Pelechas, Eleftherios Memi, Tereza Voulgari, Paraskevi V. Drosos, Alexandros A. Rheumatol Ther Case Report Psoriatic arthritis (PsA) is a unique inflammatory arthritis due to the fact that patients have to deal not only with pain but also with their skin appearance, which may have a detrimental effect on their everyday lives and psychology. Treating a patient with PsA, improving both the musculoskeletal and skin symptoms is a challenge for the clinical rheumatologist. In this case, we present a patient of recalcitrant PsA to tumor necrosis factor inhibitors (TNFi) who had an exceptional improvement after administration of the interleukin-17A inhibitor (IL-17Ai) secukinumab. Springer Healthcare 2017-10-11 /pmc/articles/PMC5696296/ /pubmed/29022197 http://dx.doi.org/10.1007/s40744-017-0084-0 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Case Report
Pelechas, Eleftherios
Memi, Tereza
Voulgari, Paraskevi V.
Drosos, Alexandros A.
A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
title A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
title_full A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
title_fullStr A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
title_full_unstemmed A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
title_short A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
title_sort case of recalcitrant psoriatic arthritis to tnf inhibitors improved after administration of secukinumab, an il-17a inhibitor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696296/
https://www.ncbi.nlm.nih.gov/pubmed/29022197
http://dx.doi.org/10.1007/s40744-017-0084-0
work_keys_str_mv AT pelechaseleftherios acaseofrecalcitrantpsoriaticarthritistotnfinhibitorsimprovedafteradministrationofsecukinumabanil17ainhibitor
AT memitereza acaseofrecalcitrantpsoriaticarthritistotnfinhibitorsimprovedafteradministrationofsecukinumabanil17ainhibitor
AT voulgariparaskeviv acaseofrecalcitrantpsoriaticarthritistotnfinhibitorsimprovedafteradministrationofsecukinumabanil17ainhibitor
AT drososalexandrosa acaseofrecalcitrantpsoriaticarthritistotnfinhibitorsimprovedafteradministrationofsecukinumabanil17ainhibitor
AT pelechaseleftherios caseofrecalcitrantpsoriaticarthritistotnfinhibitorsimprovedafteradministrationofsecukinumabanil17ainhibitor
AT memitereza caseofrecalcitrantpsoriaticarthritistotnfinhibitorsimprovedafteradministrationofsecukinumabanil17ainhibitor
AT voulgariparaskeviv caseofrecalcitrantpsoriaticarthritistotnfinhibitorsimprovedafteradministrationofsecukinumabanil17ainhibitor
AT drososalexandrosa caseofrecalcitrantpsoriaticarthritistotnfinhibitorsimprovedafteradministrationofsecukinumabanil17ainhibitor

Ejemplares similares